OR WAIT null SECS
© 2021 MJH Life Sciences and Consultant Live. All rights reserved.
The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.
October 18, 2021
Travel issues related to COVID-19 were responsible for the delay in the approval of the Biologics License Application.
October 14, 2021
Data from the PAUSE clinical trial reveals that more participants experienced psoriasis relapse in the abatacept group than the ustekinumab group.
September 30, 2021
A recent press release detailed the phase 3 findings that were presented at the virtual conference, which shows that bimekizumab was well-tolerated and efficacious in patients with moderate to severe plaque psoriasis.
September 21, 2021
The treatment was approved for adult patients with plaque psoriasis in 2018.
September 15, 2021
Though the severity of the COVID-19 virus did not differ in participants with different dermatological conditions, their conditions were affected in alternate ways.
September 08, 2021
A rarity in biologic treatments for patients with moderate-to-severe plaque psoriasis, Dr. Miller notes that patients treated with guselkumab recorded overwhelmingly positive PASI scores.
August 11, 2021
The prevalence of striae distensae was notably higher in psoriasis than atopic dermatitis.
August 09, 2021
An ongoing study of the IL-17A and IL-17F inhibitor showed patients with moderate to severe plaque psoriasis achieved long-term skin clearance results.
July 22, 2021
More research is needed to understand the pathogenesis underlying this association.
July 09, 2021
A higher proportion of patients with immune-mediated diseases experienced ≥1 thromboembolic events at baseline compared to those without an IMD.